In today’s briefing:
- Apollo Hospitals Enterprise (APHS IN): Upside Momentum to Continue on Promising Business Outlook
- Legend Biotech (LEGN.US) Offer Update – The Takeover Negotiations Could Reach an Impasse?
Apollo Hospitals Enterprise (APHS IN): Upside Momentum to Continue on Promising Business Outlook
- Apollo Hospitals Enterprise (APHS IN) reported strong Q1FY25 result, with 15% revenue growth and a massive 83% jump in net profit. EBITDA margin improved to 13.3% (Q1FY24: 13.0%).
- Sequential improvement is expected in Q2 and Q3. The company believes ARPOB growth will improve over the next few quarters with stronger growth in surgical volume and better case mix.
- The company believes enhanced volume growth, improvement in case and payer mix, and a focus on cost optimization will drive margin expansion by 100bps over the next 3–4 quarters.
Legend Biotech (LEGN.US) Offer Update – The Takeover Negotiations Could Reach an Impasse?
- The rumors we’ve heard are that the acquisition price has not yet been agreed upon. Meanwhile, the management of Legend Bio and Genscript may have different views on this takeover.
- The deal has a 50-50 chance of success. If the deal breaks, this is however “a good news” for the investors of Genscript, whose key performance contributor is Legend Bio.
- The commercialization potential of Carvykti has not yet been fully realized. Regardless of whether there is a takeover offer or not, Legend Bio is still considered a high quality asset.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
